CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses.

@article{Hammitzsch2015CBP30AS,
  title={CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses.},
  author={A Hammitzsch and Cynthia Tallant and Oleg Fedorov and Alison O'Mahony and Paul E Brennan and Duncan Alexander Hay and Fernando Oneissi Martinez and M Hussein Al-Mossawi and Jelle de Wit and Matteo Vecellio and Christopher Wells and Paul B. Wordsworth and Susanne M{\"u}ller and Stefan Knapp and Paul Bowness},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2015},
  volume={112 34},
  pages={
          10768-73
        }
}
Th17 responses are critical to a variety of human autoimmune diseases, and therapeutic targeting with monoclonal antibodies against IL-17 and IL-23 has shown considerable promise. Here, we report data to support selective bromodomain blockade of the transcriptional coactivators CBP (CREB binding protein) and p300 as an alternative approach to inhibit human Th17 responses. We show that CBP30 has marked molecular specificity for the bromodomains of CBP and p300, compared with 43 other… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 42 CITATIONS

Ectopic protein interactions within BRD4-chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2017
VIEW 16 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

CBP/p300: intramolecular and intermolecular regulations

  • Frontiers in Biology
  • 2018
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Epigenetics, microbiota, and intraocular inflammation: New paradigms of immune regulation in the eye

  • Progress in Retinal and Eye Research
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

Similar Papers

Loading similar papers…